We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · September 29, 2022

Efficacy and Safety of Modified Nivolumab/Ipilimumab Dosing Regimen for Patients With Advanced RCC

BMJ Open

 

Additional Info

BMJ Open
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
BMJ Open 2022 Sep 14;12(9)e058396, DJ George, DR Spigel, LN Gordan, ST Kochuparambil, AM Molina, J Yorio, A Rezazadeh Kalebasty, H McKean, N Tchekmedyian, SS Tykodi, J Zhang, M Askelson, JL Johansen, TE Hutson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading